FIB-4 Index emerges as non-invasive biomarker for congestion and prognosis in heart failure
Background
Heart failure (HF) is a prevalent and complex syndrome with high mortality and readmission rates, particularly in older populations, imposing significant healthcare costs. Current therapeutic strategies have improved outcomes, but there remains a critical need for novel risk factors and prognostic scores to enhance risk stratification and enable earlier, more timely therapeutic decisions. The heart-liver axis is a well-established connection where right ventricular dysfunction (RVD) in HF leads to elevated right atrial pressure, causing hepatic venous congestion, sinusoidal dilatation, and progressive liver fibrosis, which can culminate in cardiac cirrhosis. This hepatic involvement is closely linked to HF progression and poor prognosis, suggesting that biomarkers of liver fibrosis could also hold significant cardiovascular prognostic value.
Why It Matters
The identification of the FIB-4 Index as a potential non-invasive biomarker for heart failure congestion and prognosis offers a significant advancement in patient management. This readily available and inexpensive index, derived from routine lab tests, could enable earlier diagnosis and more precise risk stratification for HF patients, especially those at high risk. Integrating FIB-4 into clinical assessment could guide more timely therapeutic interventions, potentially reducing hospital readmissions and improving long-term outcomes. While the specific protocol for its use in HF prognostication is still evolving, this research highlights a practical, accessible tool that leverages the known cardio-hepatic connection to enhance prognostic capabilities beyond traditional markers.
heart failure
hf
fib-4 index
biomarker
prognosis
congestion